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Available online xxxxObjectives: The production of reference materials for quantifying pneumococcal antibody concentrations
relies upon large scale vaccination. An alternative simple, reproducible protocol has been developed for the
afﬁnity puriﬁcation of 23 serotype anti-pneumococcal capsular polysaccharide (PCP) IgG immunoglobulins.
Design & Methods: The puriﬁcation protocol utilised IgG fractionation, capsular polysaccharide (CPS)
adsorption, and afﬁnity chromatography using Pneumovax®-Sepharose. Puriﬁcation efﬁciency and method
reproducibility were assessed by comparison of 4 batches of anti-PCP IgG. Immunoglobulin composition was
determined using nephelometry and functionality was evaluated using VaccZyme™ ELISAs.
Results: Anti-PCP IgG preparations were ≥95% pure by SDS-PAGE analysis with no contaminating IgA or IgM
immunoglobulins or IgG antigen speciﬁc antibodies towards haemophilus inﬂuenzae b, diphtheria toxoid or
tetanus toxoid. The predominant IgG subclass in the preparation was IgG2.
Conclusions: This novel puriﬁcation procedure produced highly speciﬁc anti-PCP IgG preparations that
compared well to both Lot 89SF and 007sp international serum standards and could be used as an alternative
method for the production of reference materials.
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IgG1. Introduction
Historically, assays for quantifying pneumococcal antibody concen-
trations relied upon the use of the reference material Lot 89SF. Lot
89SF was produced using pooled serum specimens from 17 adults im-
munized with Pneumovax® [1]. Lot 89SF has now been superseded
by a new reference serum, 007sp, which was developed using pooled
plasma samples from 262 adults immunized with Pneumovax® [2].
For both Lot 89SF and 007sp no additional puriﬁcation steps were
employed.
Large scale vaccination of healthy volunteers requires question-
naires to prove medical validity and considerable co-ordination in
order to obtain the material. In addition to IgG, in response to
Pneumovax® IgM and IgA will also be produced [3]. The binding of all
three antibodies to their target epitopes and opsonisation activities
will be heavily inﬂuenced by the presence of each antibody presumably
through epitope competition and steric interaction [3,4]. This may
therefore affect estimation of the IgG concentrations if IgA and IgM are
not ﬁrst removed. We hypothesised that with the provision of alterna-
tive starting material and the use of a simple puriﬁcation procedure. Parker).
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16/j.clinbiochem.2016.08.009we could produce a highly puriﬁed preparation of anti-pneumococcal
capsular polysaccharide IgG antibodies.
The current study reports a simple alternativemethod for the gener-
ation of IgG anti-pneumococcal referencematerial that does not require
a large scale vaccination programme and is free from antigen speciﬁc
IgA and IgM. This methodology uses a 3-step column chromatography
protocol to produce PCP IgG-speciﬁc antisera and allows quantiﬁcation
of the PCP-IgG for standardisation purposes.2. Materials and methods
2.1. Puriﬁcation procedures
2.1.1. Preparation of CPS-Sepharose
Thirty milligrams of Streptococcus CPS (Statens Serum Institut,
Copenhagen, Denmark) were reconstituted to 2 mg/ml in coupling
buffer (0.1MNaHCO3, 0.5MNaCl, pH adjusted to 8.1with 0.5M sodium
borate) and incubated with 15 ml of N-hydroxysuccinimide (NHS)-
activated Sepharose (GE Healthcare, Amersham, UK) for 20 h at room
temperature. The resulting matrix was poured into a gravity-ﬂow
column (Bio-Rad, California, USA) and the unbound eluate collected.
The unreacted active groups on the material were blocked for 2 h with
0.2 M Tris pH 8.0 and then alternately washed for 3 cycles with 0.1 Mmists.
of anti-pneumococcal capsular polysaccharide IgG immunoglobulins,
Fig. 1. Dot blot of Pneumovax polysaccharides: before (ST), after oxidation with 10 mM
periodate (OX) and subsequent reductive amination (OXRA).
Fig. 2. SDS-PAGE analysis of four different afﬁnity puriﬁed anti PCP IgG immunoglobulin
batches. 1 μg total protein per batch (1 A, 1B, 2 and 3) was loaded into each lane and
separated under reduced or non-reduced conditions as per Materials and Methods.
Under non-reduced conditions (left hand panel), only one protein band was observed
corresponding to an intact immunoglobulin. The mobilities of the immunoglobulin were
similar in each batch. Under reduced conditions (right hand panel), three protein bands
were observed corresponding to intact immunoglobulin, heavy and light chains. The
mobilities of intact immunoglobulins, heavy and light chains were comparable between
each batch.
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containing 0.5 M NaCl.
2.1.2. Preparation of Pneumovax-Sepharose
A total of 3.5 mg of each of the 23 Pneumovax serotypes (Sanoﬁ
Pasteur, Lyon, France) were pooled, concentrated to 15 ml, and buffer
exchanged into 0.5 M NaCl (Centricon plus 70, 10 kDa cut-off mem-
brane, EMD Millipore, Massachusetts, USA). Sodium acetate (0.5 ml of
1 M, pH 5.5) was added to the polysaccharides and allowed to oxidise
with 10 mM sodium periodate for 1 h in the dark. Excess periodate
was quenched with 1% glycerol and removed by desalting on a Hiprep
Sephadex G25 column (GE Healthcare), equilibrated in 50 mM potassi-
um phosphate 150mMNaCl pH 7.4. The oxidised polysaccharides were
then mixed with 10 g of epoxy-1,6-diaminohexane (EAH)-Sepharose
4B (GE Healthcare) for 1 h at room temperature. Reductive amidation
using sodium-cyanoborohydride (Sigma-Aldrich, Missouri, USA) was
achieved with 40 mg initially and a subsequent addition of 10 mg, for
2 days at room temperature. 20 mg of sodium borohydride was then
added to quench the reaction. The Pneumovax-coupled Sepharose
(10 ml) was washed and blocked as described for the CPS coupled
Sepharose.
2.1.3. Pooled donor serum
Healthy donor plasma (typically 5–10 donors) was obtained from
expired stock (Bio Products Ltd., Elstree, UK). The plasma was pooled,
preserved with 0.099% Sodium Azide, 5 mg/ml EACA, 1 mM EDTA,
2 mM Benzamidine HCl, clotted and ﬁltered to produce serum. All pro-
cedures were performed at 4 °C.
2.1.4. Puriﬁcation of anti-PCP IgG immunoglobulins
IgG immunoglobulins were precipitated from pooled donor serum
(2 L) with 40% ammonium sulphate and puriﬁed using DE52 anion-
exchange chromatography (loading buffer: 10 mM sodium phosphate
pH 7.0) [5]. Adsorption and afﬁnity chromatography were performed
sequentially using CPS- and Pneumovax-linked Sepharose, respectively
(loading buffer: 25 mM sodium phosphate, 0.15 M NaCl, 1 mM EDTA,
0.1% EACA, 0.01% benzamidine, 0.05% v/v sodium azide, pH 7.0; elution
buffer: 0.1 M glycine, pH 3.0 containing 10% v/v glycerol and 0.05% v/v
Proclin preservative). Elution fractions were neutralised with 10%
volume 2 M Tris, 1.5 M NaCl, pH 8.0, dialysed against fully preserved
PBS buffer (25 mM sodium phosphate, 0.15 M NaCl, 1 mM EDTA, 0.1%
EACA, 0.01% benzamidine, 0.05% v/v sodium azide, pH 7.0) and stored
at−80 °C.
Two batches of the PCP IgG preparation (1 A and 1B) were puriﬁed
from the same pool of serum, and two further independent batches
were prepared from separate pools of sera (batches 2 and 3).
2.2. Analytical procedures
The efﬁciency of CPS-Sepharose coupling was determined by dot
blot using standard procedures. Analysis of the starting material and
unbound material was accomplished with a biotinylated HAA lectin
probe and visualised with Streptavidin peroxidase (both Sigma, UK).
Dot blots probed with human anti-PCP antisera were used to conﬁrm
retention of activity following coupling of Pneumovax to Sepharose.
The blot was probedwith PCP-positive human antisera (1:250), follow-
ed by anti-IgG-HRP (1:1000), and visualisation with AEC.
The concentration of the PCP polysaccharideswas estimated using the
Phenol-Sulphuric acid procedure [6] against a calibrator composed of an
equimolar mixture of glucose, galactose and N-acetyl-glucosamine.
Protein concentration was measured by the Bicinchoninic acid assay
(BCA) procedure (Gamma Globulin Std., Thermo-Pierce, UK).
Concentrations of IgG, IgA, IgM and IgG subclasses were determined
using commercially available nephelometric assays (The Binding Site
Group Ltd., Birmingham, UK) analysed using a BN™II analyser (Siemens
Healthcare Ltd., Marburg, Germany). To assess functionality and thePlease cite this article as: A.R. Parker, et al., Puriﬁcation and characterisation
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were tested in the following VaccZyme™ ELISAs according to
manufacturer's instructions: PCP IgG, PCP IgA, PCP IgM, Tetanus toxoid
IgG, Diphtheria Toxoid IgG and Haemophilus inﬂuenzae type b IgG
(The Binding Site Group Ltd).
SDS-PAGEwas conducted using 4–12% NUPAGE® gels (Thermoﬁsher
Scientiﬁc Inc., Massachusetts USA) with a pH 6.0 MOPS running buffer
as described in the manufacturer's instructions. Silver staining of the
gels was accomplished using the BioRad silver stain kit.
Serotype speciﬁc ELISAs, similar to those previously reported
(without 22F absorption [2]) and Luminex technology [7] were
employed to determine the relative concentration of serotypes in
all batches.2.3. Ethical Considerations
This project did not require ethical approval. Remnants of specimens
collected for routine diagnostic testing were used in accordance with
the Declaration of Helsinki.of anti-pneumococcal capsular polysaccharide IgG immunoglobulins,
Table 1
IgG, IgA and IgM concentrations and IgG subclass composition of anti-PCP IgG batches 1 A,
1B, 2 and 3.
Batch
IgG IgA IgM % IgG subclass composition
(g/L) (g/L) (g/L) G1 G2 G3 G4
Pool 1 (A) 2.09 b0.021 b0.009 16 82 b1 b1
Pool 1 (B) 1.23 b0.021 b0.009 18 81 b1 b1
Pool 2 0.99 b0.021 b0.009 18 82 b1 b1
Pool 3 1.42 b0.021 b0.009 13 86 b1 b1
Table 3
Percentage assigned composition of Lot 89SF, 007sp and four batches of afﬁnity puriﬁed
anti PCP IgG antibodies.
Serotype 89SFa 007spb Sample 1 A Sample 1B Sample 2 Sample 3
1 2.9 4.3 1.7 2.4 0.3 2.3
2 5.6 4.3 5.6 5.3 3.8
3 1.1 0.8 1.8 2.0 1.1 1.2
4 1.9 1.8 2.7 2.3 1.8 1.4
5 2.7 4.1 5.5 3.4 2.1 4.0
6B 7.8 5.0 9.8 10.9 0.6 4.0
7F 2.4 4.6 3.2 3.0 1.8 1.2
8 2.4 7.1 2.4 2.1 1.9 2.1
9 N 3.6 6.2 2.2 0.4 2.2
9 V 3.2 3.6 2.0 7.3 2.8 5.8
10 A 3.1 6.5 4.2 4.2 2.9 9.6
11 A 2.9 2.7 4.1 5.0 6.7 3.9
12F 0.8 1.2 1.8 1.8 1.1 1.9
14 12.8 21.0 7.8 7.2 9.6 0.5
15B 7.6 8.4 4.5 6.5 24.7 4.0
17F 4.7 4.1 5.1 4.4 5.2
18C 2.1 3.9 1.6 2.0 0.6 0.6
19F 6.0 3.3 3.1 0.5 13.6 3.9
19 A 8.6 7.3 0.3 3.6 0.6 2.5
20 4.0 7.6 9.0 4.4 14.6
22F 4.7 5.3 5.0 7.5 6.7 10.6
23F 3.7 3.2 11.6 0.5 0.6 1.5
33F 5.5 5.7 4.9 6.0 6.2 13.0
Total % 100 100 100 100 100 100
a Calculated using data from [1,9]
b Calculated using data from [2,10].
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Kruskal-Wallis statistical test was used assess signiﬁcance. P values
b0.05 were regarded as signiﬁcant. Statistical tests and Coefﬁcient of
variation (CV) were calculated using Graph Pad Prism statistical soft-
ware version 5.04.
3. Results
3.1. Coupling efﬁciency
A dot blot for CPS probed with HAA lectin (speciﬁc for GalNAc resi-
dues in CPS [8]) showed that CPS had bound to the Sepharose and all
unbound CPS had been removed by thewashing step. The 15ml column
was sufﬁcient to remove all the CPS antibodies present in the IgG pool in
a single pass (data not shown). The phenol-sulphuric acid assay showed
that 80% of the PCP-polysaccharides had coupled to the EAH-Sepharose.
Periodate oxidation followed by reductive amination may cleave
adjacent cis- hydroxyls in some monosaccharides. This could result in
epitope alteration. It is therefore important to show that following this
modiﬁcation the PCP polysaccharides still retain activity. A dot blot of
polysaccharidematerial taken at the start, after oxidation and after sub-
sequent reductive amination, suggested the Pneumovax coupling pro-
cess had not led to a signiﬁcant loss of epitopes (Fig. 1).
3.2. Analysis of puriﬁed PCP IgG immunoglobulins
In total, 7 g of IgG was obtained from a 2 L volume of serum, which
resolved as single band using coomassie SDS-PAGE (data not shown).
The adsorption and afﬁnity puriﬁcation protocol yielded between 10
and 15 mg of PCP IgG from 7 g of total IgG.
All four preparations of anti-PCP IgG were N95% pure by silver
stained SDS-PAGE with comparable gel mobilities (Fig. 2). There was
no detectable IgA or IgM in any of the batches and the predominant
IgG subclass was IgG2 (Table 1). The CV for the percentage subclass
composition across four preparations was 11.9% for IgG1 and 3.2% for
IgG2. The percentage composition of IgG3 and IgG4 was b1% in each
of the batches. Each batch had high IgG reactivity to the Pneumovax an-
tigen (11.7% CV) but not to tetanus, diphtheria or haemophilus antigens
(Table 2).
3.3. Serotype Analysis
The serotype composition of Lot 89SF, 007sp and the four batches of
anti-PCP IgG were compared (Table 3). There were no signiﬁcantTable 2
Levels of anti-Pneumococcal, Diphtheria, Haemophilus and Tetanus IgG antibodies in the anti-
Pneumococcal mg/l Diphtheria IU
Pool 1 (A) 270 b0.004
Pool 1 (B) 226.2 b0.004
Pool 2 208.2 b0.004
Pool 3 270 b0.004
Please cite this article as: A.R. Parker, et al., Puriﬁcation and characterisation
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(p= 0.57).
3.4. Reactivity of Anti-PCP IgG
The reactivity of each puriﬁed IgG batchwas comparable to the reac-
tivity of both 89SF and 007sp in the PCP IgG ELISA (Fig. 3). There were
no signiﬁcant differences between any of the curves (p= 0.98).
4. Discussion
In this study we have demonstrated a simple 3-step adsorption and
afﬁnity chromatography method for purifying anti-PCP IgG immuno-
globulins from healthy donor serum. Rather than large scale vaccina-
tion, the use of donor serum as raw material is a simpler method for
the production of reference material. After crude separation of the
total IgG from IgA and IgM, anionic ion exchange chromatography was
used to further purify the IgG fraction. Non protective anti-CPS antibod-
ies [11] were removed using a CPS-Sepharose column and the ﬁnal
puriﬁed preparation separated on a Pneumovax-Sepharose afﬁnity
column.
Using this novel method we have produced IgG preparations which
are chemically and functionally pure. All four anti-PCP IgG preparations
were found to have similar SDS-PAGE purity proﬁles, total immuno-
globulin concentrations, proﬁles of vaccine inducible antibodies, IgG
subclass compositions and reactivity suggesting acceptable and compa-
rable intra- and inter-batch reproducibility. Importantly, the IgG prepa-
rations had undetectable levels of IgA and IgM. Afﬁnity puriﬁcation of
Pneumovax-speciﬁc antibodies has previously been published [12],PCP IgG preparations.
/ml Haemophilusmg/l Tetanus IU/ml
b0.11 b0.01
b0.11 b0.01
b0.11 b0.01
b0.11 b0.01
of anti-pneumococcal capsular polysaccharide IgG immunoglobulins,
Fig. 3. Comparison between Lot 89SF, 007Sp and batches 1 A, 1B, 2 and 3 in the PCP IgG
ELISA. Lot 89SF, 007Sp and batches 1 A, 1B, 2 and 3 were diluted to approximately
270 mg/l as a working concentration. All 6 sera were serially diluted (tripling dilutions)
a further 4 times to give ﬁnal concentrations of 90, 30, 10 and 3.3 mg/l. The CVs
between each concentration point for all 6 sera were as follows: 3.3 mg/l, 15.5%;
10 mg/l, 11.3%; 30 mg/l, 9.2%; 90 mg/l, 5.5% and 270 mg/l, 5.3%.
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CPS antibody pre-adsorption, leavingmeasurable levels of both IgA and
IgM in the ﬁnal preparation that were only 5 times lower than the
IgG concentration. The presence of IgA and IgM may inﬂuence IgG
binding [3].
The composition of IgG subclasses in the four reference preparations
was different from that found in normal serum (16–18% vs 60–70%
IgG1, 81–86% vs 20% IgG2, b1% vs 10–12% IgG3 and b1% vs 4–7%
IgG4) [13]. Although the vaccination status of the donors used in the
pooled serum was unknown, our data supports a dominant role of
IgG2 antibodies in the natural protection against pneumococcal disease
and is in agreement with previous studies documenting response to
pneumococcal polysaccharide antigens [4,11,14]. This distribution may
change in the future with the administration of Prevnar conjugate
vaccine during childhood vaccination schedules.
In the four preparations, antibodies were detected against all 23
Pneumovax serotypes and the percentage coverage of serotypes was
not signiﬁcantly different from that present in both Lot 89SF and
007sp. Correlating with the high percentage of pneumococcal IgG2 an-
tibodies, there was higher percent coverage of some of the Pneumovax
speciﬁc serotypes (12F, 20, 22F and 33F) rather than some of the
Prevnar speciﬁc serotypes (6B, 14, 18C, 19F and 23F) in the four prepa-
rations. This may be the result of increased Pneumovax vaccination
rather than Prevnar vaccination in the adult population, or increased
exposure to encapsulated organisms with serotypes speciﬁc to
Pneumovax [15].
In summary,we have provided a simple 3-step procedure for afﬁnity
puriﬁcation of PCP IgG. Modiﬁcation of this protocol could be used toPlease cite this article as: A.R. Parker, et al., Puriﬁcation and characterisation
Clin Biochem (2016), http://dx.doi.org/10.1016/j.clinbiochem.2016.08.009provide puriﬁed immunoglobulins of different classes; removal of IgG
may provide more speciﬁc IgA and IgM preparations and IgG subclass
afﬁnity columns could beused to produce subclass-speciﬁc IgG prepara-
tions. This simple proceduremay provide a valuable source of reference
materials for a variety of assays.Declaration of interest
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